Vaxcyte, Inc. (PCVX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Vaxcyte, Inc. (PCVX) trades at $58.39 with AI Score 59/100 (Grade B). Vaxcyte, Inc. is a clinical-stage biotechnology company focused on developing novel protein vaccines for bacterial infectious diseases. Market cap: $8.43B, Sector: Healthcare.
Price live · AI analysis from May 10, 2026PCVX stock analysis for 2026: Analysts have set a consensus price target of $89.00 for Vaxcyte, Inc., suggesting 52.4% upside from the current price of $58.39. The AI MoonshotScore is 59/100, indicating a neutral outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
PCVX: 2/7 perspectives are bullish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Vaxcyte, Inc. (PCVX) Healthcare & Pipeline Overview
Vaxcyte, Inc. is a clinical-stage biotechnology company specializing in novel protein vaccines, with a primary focus on combating bacterial infectious diseases. Their lead candidate, VAX-24, a 24-valent pneumococcal conjugate vaccine, is currently in Phase 1/2 clinical trials, positioning the company to address the significant unmet needs in preventing pneumococcal diseases.
What Is the Investment Thesis for PCVX?
Vaxcyte's investment thesis centers on its innovative vaccine technology and its potential to address significant unmet needs in the prevention of bacterial infectious diseases. The lead candidate, VAX-24, shows promise in providing broader coverage against pneumococcal disease compared to existing vaccines. Positive Phase 1/2 clinical trial data could serve as a major catalyst, driving investor confidence and potentially leading to partnerships or acquisitions. The company's pipeline, including VAX-XP, VAX-A1, and VAX-PG, offers further growth opportunities by targeting additional infectious diseases. However, the company faces risks associated with clinical trial outcomes, regulatory approvals, and competition from established players in the vaccine market. With a market cap of $8.43B and a beta of 1.39, Vaxcyte presents a high-growth, high-risk investment profile.
Based on FMP financials and quantitative analysis
PCVX Key Highlights
- Vaxcyte's lead vaccine candidate, VAX-24, is in Phase 1/2 clinical trials, targeting invasive pneumococcal disease and pneumonia.
- The company is developing VAX-XP to protect against emerging strains and address antibiotic resistance, showcasing their commitment to innovation.
- Vaxcyte's pipeline includes VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep, expanding their therapeutic focus.
- VAX-PG, a novel protein vaccine candidate, targets the keystone pathogen responsible for periodontitis, demonstrating their diverse approach to vaccine development.
- Vaxcyte changed its name from SutroVax, Inc. in May 2020, reflecting its evolution and strategic focus on vaccine development.
Who Are PCVX's Competitors?
PCVX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ARWR Arrowhead Pharmaceuticals, Inc. | $86.85 | +3.41% | $12.23B | 31 |
| KRYS Krystal Biotech, Inc. | $374.68 | -0.10% | $11.05B | 100 |
| ACLX Arcellx, Inc. | $115.07 | +0.02% | $6.73B | 45 |
| ALKS Alkermes plc | $54.65 | +0.13% | $9.11B | 51 |
| TGTX TG Therapeutics, Inc. | $55.21 | +3.56% | $8.45B | 70 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PCVX's Key Strengths?
- Innovative vaccine technology platform.
- Strong pipeline of vaccine candidates.
- Experienced management team.
- Focus on addressing unmet needs in infectious disease prevention.
What Are PCVX's Weaknesses?
- Clinical-stage company with no currently marketed products.
- Reliance on successful clinical trial outcomes.
- High research and development costs.
- Dependence on regulatory approvals.
What Could Drive PCVX Stock Higher?
- Announcement of Phase 1/2 clinical trial results for VAX-24.
- Initiation of clinical trials for VAX-XP.
- Continued progress in the development of VAX-A1 and VAX-PG.
- Potential for strategic partnerships or collaborations.
What Are the Key Risks for PCVX?
- Negative return on equity (-32.5%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Unfavorable clinical trial results for VAX-24 or other vaccine candidates.
- Regulatory delays or rejection of vaccine approvals.
- Competition from established vaccine manufacturers.
- High research and development costs.
- Intellectual property challenges.
What Are the Growth Opportunities for PCVX?
- Expansion of VAX-24: Vaxcyte has the opportunity to expand the use of VAX-24 beyond its current Phase 1/2 clinical trials. Positive results could lead to further clinical development and eventual commercialization, addressing a significant portion of the pneumococcal vaccine market. The global pneumococcal vaccine market is projected to reach billions of dollars in the coming years, driven by the need for broader coverage and increased efficacy.
- Development of VAX-XP: VAX-XP, designed to protect against emerging pneumococcal strains and address antibiotic resistance, represents a significant growth opportunity. As antibiotic resistance becomes an increasingly pressing global health concern, vaccines that can circumvent this issue will be highly valuable. Successful development and commercialization of VAX-XP could position Vaxcyte as a leader in addressing this critical need.
- Advancement of VAX-A1: The development of VAX-A1, a conjugate vaccine candidate targeting Group A Strep, offers another avenue for growth. Group A Strep infections are common and can lead to serious complications, creating a substantial market for an effective vaccine. Vaxcyte's focus on this area could lead to a valuable addition to its product portfolio.
- Commercialization of VAX-PG: VAX-PG, targeting the keystone pathogen responsible for periodontitis, represents a novel approach to addressing a widespread oral health issue. Periodontitis affects a significant portion of the adult population, creating a large potential market for a preventative vaccine. Successful development and commercialization of VAX-PG could establish Vaxcyte in a new therapeutic area.
- Strategic Partnerships: Vaxcyte can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its vaccine candidates. Collaborations can provide access to additional resources, expertise, and distribution networks, enhancing the company's ability to bring its products to market and maximize their impact.
What Opportunities Does PCVX Have?
- Expansion of vaccine pipeline through new targets.
- Strategic partnerships with larger pharmaceutical companies.
- Growing demand for preventative healthcare solutions.
- Addressing the increasing threat of antibiotic resistance.
What Threats Does PCVX Face?
- Competition from established vaccine manufacturers.
- Unfavorable clinical trial results.
- Regulatory hurdles and delays.
- Changing market dynamics and healthcare policies.
What Are PCVX's Competitive Advantages?
- Proprietary vaccine technology platform.
- Strong intellectual property portfolio.
- Clinical trial data demonstrating efficacy.
- Experienced management team with expertise in vaccine development.
What Does PCVX Do?
Vaxcyte, Inc., formerly known as SutroVax, Inc., was founded in 2013 and is headquartered in San Carlos, California. The company is dedicated to the development of innovative protein vaccines designed to prevent and treat bacterial infectious diseases. Vaxcyte's core technology focuses on creating vaccines that offer broad protection against prevalent and emerging bacterial strains. Their lead vaccine candidate, VAX-24, is a 24-valent investigational pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials. This vaccine aims to provide comprehensive coverage against the 24 serotypes of Streptococcus pneumoniae, which are responsible for a significant portion of invasive pneumococcal disease and pneumonia cases. Beyond VAX-24, Vaxcyte is also developing VAX-XP, a vaccine designed to protect against emerging pneumococcal strains and address the growing issue of antibiotic resistance. The company's pipeline includes VAX-A1, a conjugate vaccine candidate targeting Group A Streptococcus (GAS), a bacterium responsible for various infections, including strep throat and rheumatic fever. Additionally, Vaxcyte is developing VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis, a common and serious gum infection. Vaxcyte's strategic focus on addressing unmet needs in infectious disease prevention positions it as a key player in the biotechnology sector.
What Products and Services Does PCVX Offer?
- Develop novel protein vaccines to prevent bacterial infectious diseases.
- Focus on vaccines that offer broad protection against prevalent and emerging bacterial strains.
- Conduct clinical trials to evaluate the safety and efficacy of their vaccine candidates.
- Target unmet needs in infectious disease prevention.
- Address the growing issue of antibiotic resistance through innovative vaccine design.
- Develop conjugate vaccines targeting specific bacterial pathogens.
How Does PCVX Make Money?
- Research and development of novel protein vaccines.
- Conducting clinical trials to demonstrate safety and efficacy.
- Seeking regulatory approval from agencies like the FDA.
- Commercializing approved vaccines through partnerships or direct sales.
What Industry Does PCVX Operate In?
Vaxcyte operates within the biotechnology industry, specifically focusing on vaccine development. The global vaccine market is experiencing substantial growth, driven by increasing awareness of preventative healthcare, rising prevalence of infectious diseases, and advancements in vaccine technologies. The competitive landscape includes established pharmaceutical companies and other biotechnology firms developing vaccines for various diseases. Vaxcyte differentiates itself through its novel protein vaccine technology and its focus on addressing unmet needs in bacterial infectious diseases. The company's success depends on its ability to navigate the complex regulatory environment and effectively commercialize its vaccine candidates.
Who Are PCVX's Key Customers?
- Healthcare providers (doctors, hospitals, clinics).
- Public health organizations (government agencies).
- Individuals seeking preventative healthcare.
- Pharmacies and distributors.
How Vaxcyte, Inc. Is Valued
Vaxcyte, Inc. carries a market capitalization of $8.43B, placing it in the mid-cap category. Relative to its peer group, PCVX's quantitative score of 59/100 is roughly in line with the peer average of 59/100.
Company Profile
Vaxcyte, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Carlos, US. The company is led by CEO Grant E. Pickering. PCVX has traded publicly since 2020.
ROE -33%Key Financial Metrics
Return on equity for Vaxcyte, Inc. stands at -32.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -28.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -10.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 7.49 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -13.7%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 1/9Financial Health
Vaxcyte, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 12.95 places it in the safe zone, indicating low near-term bankruptcy risk.
FY2026 estForward Outlook
Wall Street analysts project Vaxcyte, Inc. revenue of about $25.0M for fiscal 2026, with EPS near $-8.38. The estimate reflects 5 contributing analysts.
Net buyingInsider Activity
Over the past six months, Vaxcyte, Inc. insiders filed 29 SEC Form 4 transactions — 15 sales and 14 purchases. On net that is roughly 38K shares acquired (about $1.1M) — insiders putting money in tends to read as conviction.
PCVX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Vaxcyte's recent insider buying suggests confidence in the company's future prospects, mirroring situations like executives loading up on Tesla before major milestones. The community buzz is largely positive, focusing on potential pipeline breakthroughs. Market perception sees Vaxcyte as a key player in next-gen vaccine tech. Recent developments highlight increasing partnerships and collaborations, signaling industry validation.
- Vaxcyte's innovative vaccine platform is attracting significant attention, reminiscent of Moderna's early days. Community sentiment reflects strong belief in the company's ability to disrupt the vaccine market. The market is viewing Vaxcyte as a high-growth potential biotech. New data releases are being interpreted as very promising by key opinion leaders.
Bear Case
- Recent market volatility is creating a risk-off environment, impacting growth stocks like Vaxcyte, similar to what happened to many tech stocks in early 2022. Community concerns revolve around potential delays in clinical trials, a common fear in biotech. Market perception reflects some skepticism about the timeline for commercialization. Insider selling, while not dominant, is raising some eyebrows and prompting questions about near-term expectations.
- Competition in the vaccine space is intensifying, putting pressure on Vaxcyte to deliver results quickly, much like the crowded EV market. Community sentiment shows some worry about the company's cash burn rate. The market is aware of the high regulatory hurdles involved in vaccine development. There are concerns about the scalability of Vaxcyte's manufacturing process if their vaccines are approved.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
PCVX Latest News
-
Vaxcyte Inc (PCVX) Is A Hidden Multibagger Stock To Buy Now
Yahoo! Finance: PCVX News · Jul 3, 2026
-
10 Health Care Stocks With Whale Alerts In Today’s Session
benzinga · Jun 29, 2026
-
Vaxcyte Insider Sold Shares Worth $1,338,270, According to a Recent SEC Filing
MT Newswires · Jun 29, 2026
-
Vaxcyte (PCVX) Doses Its First Patient in a Trial for a Disease With No Existing Vaccine
Yahoo! Finance: PCVX News · Jun 22, 2026
PCVX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PCVX.
Price Targets
Consensus target: $89.00
PCVX MoonshotScore
What does this score mean?
The MoonshotScore rates PCVX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Vaxcyte Inc (PCVX) Is A Hidden Multibagger Stock To Buy Now
10 Health Care Stocks With Whale Alerts In Today’s Session
Vaxcyte Insider Sold Shares Worth $1,338,270, According to a Recent SEC Filing
Vaxcyte (PCVX) Doses Its First Patient in a Trial for a Disease With No Existing Vaccine
Latest Vaxcyte, Inc. Analysis
Leadership: Grant E. Pickering
CEO
Grant E. Pickering serves as the Chief Executive Officer of Vaxcyte, Inc. His career spans several leadership roles within the biotechnology and pharmaceutical industries. Prior to joining Vaxcyte, Pickering held significant positions at leading healthcare companies, contributing to strategic planning, business development, and product commercialization. His experience includes a deep understanding of vaccine development, clinical trials, and regulatory affairs. Pickering's expertise is instrumental in guiding Vaxcyte's strategic direction and driving the company's growth.
Track Record: Under Grant Pickering's leadership, Vaxcyte has advanced its lead vaccine candidate, VAX-24, through Phase 1/2 clinical trials. He has overseen the expansion of the company's pipeline to include VAX-XP, VAX-A1, and VAX-PG, targeting additional infectious diseases. Pickering has also been instrumental in securing funding and establishing strategic partnerships to support Vaxcyte's research and development efforts.
Vaxcyte, Inc. Healthcare Stock: Key Questions Answered
What does Vaxcyte, Inc. do?
Vaxcyte, Inc. is a clinical-stage biotechnology company focused on developing novel protein vaccines to prevent or treat bacterial infectious diseases. Their lead vaccine candidate, VAX-24, is a 24-valent investigational pneumococcal conjugate vaccine currently in Phase 1/2 clinical trials, targeting invasive pneumococcal disease and pneumonia. The company is also developing vaccines to address antibiotic resistance and target other bacterial pathogens, such as Group A Strep and the keystone pathogen responsible for periodontitis. Vaxcyte aims to address unmet needs in infectious disease prevention through innovative vaccine design and development.
What do analysts say about PCVX stock?
Analyst coverage of Vaxcyte (PCVX) reflects a focus on its clinical pipeline and the potential of its vaccine candidates. Key valuation metrics include market capitalization and enterprise value, which are used to assess the company's overall worth. Growth considerations center on the successful completion of clinical trials, regulatory approvals, and the commercial potential of Vaxcyte's vaccines. Analyst consensus typically reflects expectations for future revenue growth and profitability based on these factors. However, it's important to note that analyst ratings and price targets are subject to change based on new data and market conditions.
What are the main risks for PCVX?
Vaxcyte faces several key risks inherent to the biotechnology industry. Clinical trial risk is significant, as unfavorable results for VAX-24 or other vaccine candidates could negatively impact the company's valuation. Regulatory risk is also a factor, as delays or rejection of vaccine approvals could hinder commercialization efforts. Competition from established vaccine manufacturers poses a challenge, as these companies have significant resources and market presence. Additionally, high research and development costs and potential intellectual property challenges could impact Vaxcyte's financial performance and long-term growth prospects.
How does Vaxcyte, Inc. navigate regulatory approval processes?
Vaxcyte, Inc. navigates regulatory approval processes by adhering to stringent guidelines set forth by regulatory agencies such as the FDA in the United States. The company meticulously designs and executes clinical trials to demonstrate the safety and efficacy of its vaccine candidates. Vaxcyte maintains rigorous documentation and quality control processes throughout the development and manufacturing stages. The company also engages in ongoing communication with regulatory agencies to address any concerns and ensure compliance with applicable regulations. This comprehensive approach aims to facilitate the timely and efficient approval of Vaxcyte's vaccines.
What is Vaxcyte, Inc.'s drug pipeline status?
Vaxcyte, Inc.'s drug pipeline includes several vaccine candidates in various stages of development. The lead candidate, VAX-24, is currently in Phase 1/2 clinical trials, targeting invasive pneumococcal disease and pneumonia. Vaxcyte is also developing VAX-XP to protect against emerging pneumococcal strains and address antibiotic resistance. The pipeline includes VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep, and VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis. Upcoming catalysts include the announcement of clinical trial results and the initiation of new clinical trials for various vaccine candidates.
What are the key factors to evaluate for PCVX?
Vaxcyte, Inc. (PCVX) holds an AI score of 59/100 (moderate). Analysts target $89.00 (+52%). Not financial advice.
How frequently does PCVX data refresh on this page?
PCVX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven PCVX's recent stock price performance?
Vaxcyte, Inc. (PCVX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative vaccine technology platform. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available company data and may be subject to change.
- Clinical trial outcomes are inherently uncertain and can impact future results.